As the market continues to navigate economic uncertainty, investors are increasingly looking toward smaller companies with ...

USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, July 10, 2025 /PRNewswire/ -- USA News Group News Commentary – ...

Nuvation Bio (NUVB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Nuvation Bio Inc. (NYSE:NUVB) has recently transitioned from a clinical-stage to a commercial-stage biotechnology company with the FDA approval of its flagship drug IBTROZI (taletrectinib) for the ...

Detailed price information for Nuvation Bio Inc (NUVB-N) from The Globe and Mail including charting and trades.

Nuvation Bio was founded in 2018 by biopharma industry veteran David Hung, M.D., who previously founded Medivation, Inc., which brought to patients one of the world’s leading prostate cancer ...

Nuvation Bio Inc. (NYSE:NUVB) shareholders (or potential shareholders) will be happy to see that the Founder, David Hung, recently bought a whopping US$894k worth of stock, at a price of US$1.79 ...

Nuvation Bio Inc. (NYSE:NUVB) shareholders (or potential shareholders) will be happy to see that the Founder, David Hung, recently bought a whopping US$894k worth of stock, at a price of US$1.79.

The U.S. Food and Drug Administration said on Wednesday it has approved Nuvation Bio's drug for patients with a rare and aggressive form of lung cancer.

Shares of Nuvation Bio Inc. (NYSE:NUVB – Get Free Report) have been assigned an average rating of “Buy” from the six analysts that are presently covering the company, MarketBeat reports ...

Nuvation Bio’s lead asset, taletrectinib, is poised to potentially reshape the company’s trajectory. The drug, designed to treat ROS1-positive NSCLC, is currently under priority review with a ...

Nuvation Bio was founded in 2018 by biopharma industry veteran David Hung, M.D., who previously founded Medivation, Inc., which brought to patients one of the world’s leading prostate cancer medicines ...